Drug Profile
AP 2600
Alternative Names: AP 2600Latest Information Update: 04 Sep 2023
Price :
$50
*
At a glance
- Originator Arissa Pharma
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Dyslipidaemias
Most Recent Events
- 04 Sep 2023 Discontinued - Preclinical for Dyslipidaemias in China (unspecified route)
- 28 Jul 2020 No recent reports of development identified for preclinical development in Dyslipidaemias in China
- 06 Jun 2016 Preclinical trials in Dyslipidaemias in China (unspecified route) before June 2016